Focused On-demand Library for Interferon regulatory factor 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q14653

UPID:

IRF3_HUMAN

Alternative names:

Alternative UPACC:

Q14653; A8K7L2; B2RAZ3; Q5FBY1; Q5FBY2; Q5FBY4; Q7Z5G6

Background:

Interferon regulatory factor 3 (IRF3) is a pivotal transcriptional regulator in the innate immune response against viral infections. It activates type I interferon and interferon-stimulated genes by binding to their promoters, playing a crucial role in defending against DNA and RNA viruses. IRF3 transitions from an inactive state in the cytoplasm to an active form upon viral infection, leading to its nuclear localization and the initiation of a potent immune response.

Therapeutic significance:

The association of IRF3 with encephalopathy, acute, infection-induced, 7, herpes-specific, underscores its critical role in disease processes. Understanding the role of Interferon regulatory factor 3 could open doors to potential therapeutic strategies, especially in conditions where the immune response to viral infections is pivotal.